Open label extension to the ALLEGRO study

• Research type

  Research Study

• Full title

  A multinational, multicenter, open-label, single-assignment extension of the MS-LAQ-301 (ALLEGRO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis

• IRAS ID

  27391

• Sponsor organisation

  Teva Pharmaceutical Industries Ltd

• Eudract number

  2009-012989-30

• Clinicaltrials.gov Identifier

  NCT00509145

• Research summary

  N/A

• REC name

  East Midlands - Leicester South Research Ethics Committee

• REC reference

  09/H0402/96

• Date of REC Opinion

  17 Nov 2009

• REC opinion

  Further Information Favourable Opinion